NEW YORK – Constructive Bio, a synthetic genomics startup based in Cambridge, UK, said Tuesday that it has closed a $58 million Series A financing round.
Ahren, OMX Ventures, and Paladin Capital Group led the round, joined by Fine Structure Ventures, +ND Capital, and Jonathan Milner.
In a statement, the firm said it would use the funding to "further develop Constructive Bio's groundbreaking technology that writes genomes from scratch and creates entirely new biomolecules."
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionize drug manufacturing and discovery," said Constructive Bio CEO Ola Wlodek. "This financing will enable us to accelerate bringing breakthrough products and platforms to market, which will grow our revenue through existing and new paths, ranging from exciting therapeutics to sustainable biomaterials."
Launched in 2022, Constructive Bio is a spinout from the lab of Jason Chin at the University of Cambridge, where researchers synthesized the genome of Escherichia coli in 2019. Chin, who founded the company and serves as its CSO, noted that the funding would allow the firm to "[accelerate] genome synthesis and design from years to days."
The firm offers full-genome synthesis and is able to expand the genetic code to include non-canonical amino acids.
"Constructive Bio has cutting-edge technology with exceptional near- and long-term potential," Shyam Kamadolli, managing director of Fine Structure Ventures, said in a statement. "It couples groundbreaking innovation with multiple distinct routes to market and is set to revolutionize the sustainable biomanufacturing of new products across industries."